Home > Press Releases > Neoantigen Cancer Vaccines Market

Neoantigen Cancer Vaccines Market Likely to Surpass USD 5.1 Billion by 2035

Report Code: HC-11988  |  Published in: Aug 2026, By MarketGenics  |  Number of pages: 372
Get PDF
Buy

Global Neoantigen Cancer Vaccines Market Forecast 2035:

According to the report, the global neoantigen cancer vaccines market is projected to expand from USD 0.6 billion in 2025 to USD 5.1 billion by 2035, registering a CAGR of 23.9%, the highest during the forecast period. The global neoantigen cancer vaccines market is expected to grow due to the advancement in tumor sequencing and computational neoantigen prediction, which is helping to identify more precisely the targets in patients.

The growing clinical proof of the personalized immunotherapy, along with the expansion of individualized mRNA and DNA vaccine platforms, are further reinforcing growth and adoption potential for the market. For instance, The Cancer Research Institute's report for 2026 highlights the potential of neoantigen and shared-antigen vaccines, which are scheduled for key Phase 3 readouts, and Moderna's V940, which has shown a 49% reduction in recurrence or death and 62% reduction in distant metastasis or death versus pembrolizumab alone in the Phase 2b melanoma data. The growing clinical validation, technological progress and investments in precision immunotherapy could drive up commercialization and boost the neoantigen vaccine market.                        

Key Driver, Restraint, and Growth Opportunity Shaping the Global Neoantigen Cancer Vaccines Market

The growth of neoantigen vaccines for cancer prevention is creating new market opportunities beyond traditional cancer therapy. Nouscom's NOUS-209 is aimed at 209 shared frameshift neoantigens of MSI tumors, and is being tested for cancer interception in Lynch syndrome carriers.                                              

Clinical outcomes are affected by variability in tumour biology and patient immune responses, which can enhance development uncertainty. The phasing out of BioNTech's IMcode004 Phase 2 trial of autogene cevumeran in muscle invasive urothelial carcinoma (MIUC) underscores the difficulties of bringing individualized neoantigen therapies to other treatment contexts.                           

Shared-neoantigen vaccination technologies provide the potential to increase scalability by targeting recurring mutations observed in specified patient populations. These techniques can minimize personalized manufacturing requirements, shorten production times, cut costs, and allow for wider clinical deployment while maintaining focused immune responses against tumor-specific molecular features. 

Expansion of Global Neoantigen Cancer Vaccines Market

Expansion of Clinical Applications Across Diverse Solid Tumors

  • The use of neoantigen vaccines is expanding into other solid tumors, including melanoma, pancreatic, colorectal, and lung and liver cancers, and is being evaluated in clinical trials. The wide range of tests in different tumor types allows developers to explore personalized immune responses in a range of disease contexts, increasing the patient population that can be addressed and expanding the commercial potential for neoantigen-based cancer immunotherapies.
  • The potential for prostate, bladder, and other solid tumour applications is likely to increase the patient addressable market, drive clinical adoption, and drive the overall market growth.                                     

Regional Analysis of Global Neoantigen Cancer Vaccines Market

  • North America commands the highest demand due to its advanced oncology infrastructure, concentration of biotechnology companies, genomic-sequencing capabilities, and established precision-immunotherapy ecosystem. Clinical evidence is emerging that personalized neoantigen vaccines are effective in pancreatic cancer and kidney cancer, bolstering clinical interest and activity, according to the U.S. National Cancer Institute. The region's commercialization potential is also enhanced by continued development of individualized cancer vaccines by US-based biotechnology companies.
  • Asia Pacific is experiencing accelerated growth because of the cancer burden, expansion in the Biotechnology industry, growing capabilities in the genomic-medicine industry and the growing investments in personalized oncology. Advancements in clinical research infrastructure, and the adoption of advanced immunotherapy technologies are creating favorable conditions in China, Japan, South Korea and Australia for the development of neoantigen vaccines, and increased patient access.           

Prominent players operating in the global neoantigen cancer vaccines market is Agenus Inc., BioNTech SE, Creative Biolabs, Geneos Therapeutics, Inc., Intavis Peptide Services GmbH, Moderna, Inc., NEC Bio B.V., Neogene Therapeutics (AstraZeneca plc), Nouscom AG, Nykode Therapeutics AS, The Merck Group, Others.      

The global neoantigen cancer vaccines market has been segmented as follows:

Global Neoantigen Cancer Vaccines Market Analysis, By Vaccine Type

  • Personalized Neoantigen Vaccines
  • Off-the-Shelf Neoantigen Vaccines

Global Neoantigen Cancer Vaccines Market Analysis, By Technology Platform

  • mRNA-based Vaccines
  • Peptide-based Vaccines
  • DNA-based Vaccines
  • Dendritic Cell-based Vaccines
  • Viral Vector-based Vaccines
  • Lipid Nanoparticle (LNP)-based Vaccines
  • Cell-based Vaccines
  • Synthetic Long Peptide (SLP) Vaccines
  • Others

Global Neoantigen Cancer Vaccines Market Analysis, By Neoantigen Type

  • Somatic Mutation-derived Neoantigens
  • Frameshift Mutation Neoantigens
  • Fusion-derived Neoantigens
  • Splice Variant Neoantigens
  • Shared Tumor-associated Neoantigens
  • Tumor-specific Neoantigens

Global Neoantigen Cancer Vaccines Market Analysis, By Cancer Type

  • Melanoma
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer
  • Pancreatic Cancer
  • Bladder/Urothelial Cancer
  • Renal Cell Carcinoma
  • Head & Neck Cancer
  • Glioblastoma/Brain Tumors
  • Others (Breast, Ovarian, Hepatocellular, etc.)

Global Neoantigen Cancer Vaccines Market Analysis, By Delivery Route

  • Intradermal
  • Subcutaneous
  • Intramuscular
  • Intravenous
  • Intratumoral

Global Neoantigen Cancer Vaccines Market Analysis, By Therapy Type

  • Monotherapy
  • Combination with Immune Checkpoint Inhibitors
  • Combination with Chemotherapy
  • Combination with Targeted Therapy
  • Combination with Radiotherapy
  • Combination with Cell Therapy
  • Combination with Cytokine Therapy

Global Neoantigen Cancer Vaccines Market Analysis, By Development Phase

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Approved/Commercial

Global Neoantigen Cancer Vaccines Market Analysis, By End User

  • Hospitals
  • Cancer Specialty Centers
  • Academic & Research Institutes
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Contract Manufacturing Organizations

Global Neoantigen Cancer Vaccines Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Neoantigen Cancer Vaccines Market Outlook
      • 2.1.1. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Advances in next-generation sequencing and neoantigen prediction technologies
        • 4.1.1.2. Rising adoption of personalized and precision oncology approaches
        • 4.1.1.3. Growing integration of mRNA platforms and combination immunotherapy
      • 4.1.2. Restraints
        • 4.1.2.1. High complexity and cost of patient-specific vaccine manufacturing
        • 4.1.2.2. Tumor heterogeneity and immunosuppressive tumor microenvironment limiting clinical efficacy
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Neoantigen Cancer Vaccines Market Demand
      • 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Neoantigen Cancer Vaccines Market Analysis, by Vaccine Type
    • 6.1. Key Segment Analysis
    • 6.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Vaccine Type, 2021-2035
      • 6.2.1. Personalized Neoantigen Vaccines
      • 6.2.2. Off-the-Shelf Neoantigen Vaccines
  • 7. Global Neoantigen Cancer Vaccines Market Analysis, by Technology Platform
    • 7.1. Key Segment Analysis
    • 7.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology Platform, 2021-2035
      • 7.2.1. mRNA-based Vaccines
      • 7.2.2. Peptide-based Vaccines
      • 7.2.3. DNA-based Vaccines
      • 7.2.4. Dendritic Cell-based Vaccines
      • 7.2.5. Viral Vector-based Vaccines
      • 7.2.6. Lipid Nanoparticle (LNP)-based Vaccines
      • 7.2.7. Cell-based Vaccines
      • 7.2.8. Synthetic Long Peptide (SLP) Vaccines
      • 7.2.9. Others
  • 8. Global Neoantigen Cancer Vaccines Market Analysis, by Neoantigen Type
    • 8.1. Key Segment Analysis
    • 8.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Neoantigen Type, 2021-2035
      • 8.2.1. Somatic Mutation-derived Neoantigens
      • 8.2.2. Frameshift Mutation Neoantigens
      • 8.2.3. Fusion-derived Neoantigens
      • 8.2.4. Splice Variant Neoantigens
      • 8.2.5. Shared Tumor-associated Neoantigens
      • 8.2.6. Tumor-specific Neoantigens
  • 9. Global Neoantigen Cancer Vaccines Market Analysis, by Cancer Type
    • 9.1. Key Segment Analysis
    • 9.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Cancer Type, 2021-2035
      • 9.2.1. Melanoma
      • 9.2.2. Non-Small Cell Lung Cancer (NSCLC)
      • 9.2.3. Colorectal Cancer
      • 9.2.4. Pancreatic Cancer
      • 9.2.5. Bladder/Urothelial Cancer
      • 9.2.6. Renal Cell Carcinoma
      • 9.2.7. Head & Neck Cancer
      • 9.2.8. Glioblastoma/Brain Tumors
      • 9.2.9. Others (Breast, Ovarian, Hepatocellular, etc.)
  • 10. Global Neoantigen Cancer Vaccines Market Analysis, by Delivery Route
    • 10.1. Key Segment Analysis
    • 10.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Delivery Route, 2021-2035
      • 10.2.1. Intradermal
      • 10.2.2. Subcutaneous
      • 10.2.3. Intramuscular
      • 10.2.4. Intravenous
      • 10.2.5. Intratumoral
  • 11. Global Neoantigen Cancer Vaccines Market Analysis, by Therapy Type
    • 11.1. Key Segment Analysis
    • 11.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapy Type, 2021-2035
      • 11.2.1. Monotherapy
      • 11.2.2. Combination with Immune Checkpoint Inhibitors
      • 11.2.3. Combination with Chemotherapy
      • 11.2.4. Combination with Targeted Therapy
      • 11.2.5. Combination with Radiotherapy
      • 11.2.6. Combination with Cell Therapy
      • 11.2.7. Combination with Cytokine Therapy
  • 12. Global Neoantigen Cancer Vaccines Market Analysis, by Development Phase
    • 12.1. Key Segment Analysis
    • 12.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Development Phase, 2021-2035
      • 12.2.1. Preclinical
      • 12.2.2. Phase I
      • 12.2.3. Phase II
      • 12.2.4. Phase III
      • 12.2.5. Approved/Commercial
  • 13. Global Neoantigen Cancer Vaccines Market Analysis, by End User
    • 13.1. Key Segment Analysis
    • 13.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 13.2.1. Hospitals
      • 13.2.2. Cancer Specialty Centers
      • 13.2.3. Academic & Research Institutes
      • 13.2.4. Biotechnology Companies
      • 13.2.5. Pharmaceutical Companies
      • 13.2.6. Contract Manufacturing Organizations
  • 14. Global Neoantigen Cancer Vaccines Market Analysis, by Region
    • 14.1. Key Findings
    • 14.2. Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 14.2.1. North America
      • 14.2.2. Europe
      • 14.2.3. Asia Pacific
      • 14.2.4. Middle East
      • 14.2.5. Africa
      • 14.2.6. South America
  • 15. North America Neoantigen Cancer Vaccines Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. North America Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Vaccine Type
      • 15.3.2. Technology Platform
      • 15.3.3. Neoantigen Type
      • 15.3.4. Cancer Type
      • 15.3.5. Delivery Route
      • 15.3.6. Therapy Type
      • 15.3.7. Development Phase
      • 15.3.8. End User      
      • 15.3.9. Country
        • 15.3.9.1. USA
        • 15.3.9.2. Canada
        • 15.3.9.3. Mexico
    • 15.4. USA Neoantigen Cancer Vaccines Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Vaccine Type
      • 15.4.3. Technology Platform
      • 15.4.4. Neoantigen Type
      • 15.4.5. Cancer Type
      • 15.4.6. Delivery Route
      • 15.4.7. Therapy Type
      • 15.4.8. Development Phase
      • 15.4.9. End User
    • 15.5. Canada Neoantigen Cancer Vaccines Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Vaccine Type
      • 15.5.3. Technology Platform
      • 15.5.4. Neoantigen Type
      • 15.5.5. Cancer Type
      • 15.5.6. Delivery Route
      • 15.5.7. Therapy Type
      • 15.5.8. Development Phase
      • 15.5.9. End User
    • 15.6. Mexico Neoantigen Cancer Vaccines Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Vaccine Type
      • 15.6.3. Technology Platform
      • 15.6.4. Neoantigen Type
      • 15.6.5. Cancer Type
      • 15.6.6. Delivery Route
      • 15.6.7. Therapy Type
      • 15.6.8. Development Phase
      • 15.6.9. End User
  • 16. Europe Neoantigen Cancer Vaccines Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Europe Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Vaccine Type
      • 16.3.2. Technology Platform
      • 16.3.3. Neoantigen Type
      • 16.3.4. Cancer Type
      • 16.3.5. Delivery Route
      • 16.3.6. Therapy Type
      • 16.3.7. Development Phase
      • 16.3.8. End User
      • 16.3.9. Country
        • 16.3.9.1. Germany
        • 16.3.9.2. United Kingdom
        • 16.3.9.3. France
        • 16.3.9.4. Italy
        • 16.3.9.5. Spain
        • 16.3.9.6. Netherlands
        • 16.3.9.7. Nordic Countries
        • 16.3.9.8. Poland
        • 16.3.9.9. Russia & CIS
        • 16.3.9.10. Rest of Europe
    • 16.4. Germany Neoantigen Cancer Vaccines Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Vaccine Type
      • 16.4.3. Technology Platform
      • 16.4.4. Neoantigen Type
      • 16.4.5. Cancer Type
      • 16.4.6. Delivery Route
      • 16.4.7. Therapy Type
      • 16.4.8. Development Phase
      • 16.4.9. End User
    • 16.5. United Kingdom Neoantigen Cancer Vaccines Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Vaccine Type
      • 16.5.3. Technology Platform
      • 16.5.4. Neoantigen Type
      • 16.5.5. Cancer Type
      • 16.5.6. Delivery Route
      • 16.5.7. Therapy Type
      • 16.5.8. Development Phase
      • 16.5.9. End User
    • 16.6. France Neoantigen Cancer Vaccines Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Vaccine Type
      • 16.6.3. Technology Platform
      • 16.6.4. Neoantigen Type
      • 16.6.5. Cancer Type
      • 16.6.6. Delivery Route
      • 16.6.7. Therapy Type
      • 16.6.8. Development Phase
      • 16.6.9. End User
    • 16.7. Italy Neoantigen Cancer Vaccines Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Vaccine Type
      • 16.7.3. Technology Platform
      • 16.7.4. Neoantigen Type
      • 16.7.5. Cancer Type
      • 16.7.6. Delivery Route
      • 16.7.7. Therapy Type
      • 16.7.8. Development Phase
      • 16.7.9. End User
    • 16.8. Spain Neoantigen Cancer Vaccines Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Vaccine Type
      • 16.8.3. Technology Platform
      • 16.8.4. Neoantigen Type
      • 16.8.5. Cancer Type
      • 16.8.6. Delivery Route
      • 16.8.7. Therapy Type
      • 16.8.8. Development Phase
      • 16.8.9. End User
    • 16.9. Netherlands Neoantigen Cancer Vaccines Market
      • 16.9.1. Country Segmental Analysis
      • 16.9.2. Vaccine Type
      • 16.9.3. Technology Platform
      • 16.9.4. Neoantigen Type
      • 16.9.5. Cancer Type
      • 16.9.6. Delivery Route
      • 16.9.7. Therapy Type
      • 16.9.8. Development Phase
      • 16.9.9. End User
    • 16.10. Nordic Countries Neoantigen Cancer Vaccines Market
      • 16.10.1. Country Segmental Analysis
      • 16.10.2. Vaccine Type
      • 16.10.3. Technology Platform
      • 16.10.4. Neoantigen Type
      • 16.10.5. Cancer Type
      • 16.10.6. Delivery Route
      • 16.10.7. Therapy Type
      • 16.10.8. Development Phase
      • 16.10.9. End User
    • 16.11. Poland Neoantigen Cancer Vaccines Market
      • 16.11.1. Country Segmental Analysis
      • 16.11.2. Vaccine Type
      • 16.11.3. Technology Platform
      • 16.11.4. Neoantigen Type
      • 16.11.5. Cancer Type
      • 16.11.6. Delivery Route
      • 16.11.7. Therapy Type
      • 16.11.8. Development Phase
      • 16.11.9. End User
    • 16.12. Russia & CIS Neoantigen Cancer Vaccines Market
      • 16.12.1. Country Segmental Analysis
      • 16.12.2. Vaccine Type
      • 16.12.3. Technology Platform
      • 16.12.4. Neoantigen Type
      • 16.12.5. Cancer Type
      • 16.12.6. Delivery Route
      • 16.12.7. Therapy Type
      • 16.12.8. Development Phase
      • 16.12.9. End User
    • 16.13. Rest of Europe Neoantigen Cancer Vaccines Market
      • 16.13.1. Country Segmental Analysis
      • 16.13.2. Vaccine Type
      • 16.13.3. Technology Platform
      • 16.13.4. Neoantigen Type
      • 16.13.5. Cancer Type
      • 16.13.6. Delivery Route
      • 16.13.7. Therapy Type
      • 16.13.8. Development Phase
      • 16.13.9. End User
  • 17. Asia Pacific Neoantigen Cancer Vaccines Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Asia Pacific Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Vaccine Type
      • 17.3.2. Technology Platform
      • 17.3.3. Neoantigen Type
      • 17.3.4. Cancer Type
      • 17.3.5. Delivery Route
      • 17.3.6. Therapy Type
      • 17.3.7. Development Phase
      • 17.3.8. End User
      • 17.3.9. Country
        • 17.3.9.1. China
        • 17.3.9.2. India
        • 17.3.9.3. Japan
        • 17.3.9.4. South Korea
        • 17.3.9.5. Australia and New Zealand
        • 17.3.9.6. Indonesia
        • 17.3.9.7. Malaysia
        • 17.3.9.8. Thailand
        • 17.3.9.9. Vietnam
        • 17.3.9.10. Rest of Asia Pacific
    • 17.4. China Neoantigen Cancer Vaccines Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Vaccine Type
      • 17.4.3. Technology Platform
      • 17.4.4. Neoantigen Type
      • 17.4.5. Cancer Type
      • 17.4.6. Delivery Route
      • 17.4.7. Therapy Type
      • 17.4.8. Development Phase
      • 17.4.9. End User
    • 17.5. India Neoantigen Cancer Vaccines Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Vaccine Type
      • 17.5.3. Technology Platform
      • 17.5.4. Neoantigen Type
      • 17.5.5. Cancer Type
      • 17.5.6. Delivery Route
      • 17.5.7. Therapy Type
      • 17.5.8. Development Phase
      • 17.5.9. End User
    • 17.6. Japan Neoantigen Cancer Vaccines Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Vaccine Type
      • 17.6.3. Technology Platform
      • 17.6.4. Neoantigen Type
      • 17.6.5. Cancer Type
      • 17.6.6. Delivery Route
      • 17.6.7. Therapy Type
      • 17.6.8. Development Phase
      • 17.6.9. End User
    • 17.7. South Korea Neoantigen Cancer Vaccines Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Vaccine Type
      • 17.7.3. Technology Platform
      • 17.7.4. Neoantigen Type
      • 17.7.5. Cancer Type
      • 17.7.6. Delivery Route
      • 17.7.7. Therapy Type
      • 17.7.8. Development Phase
      • 17.7.9. End User
    • 17.8. Australia and New Zealand Neoantigen Cancer Vaccines Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Vaccine Type
      • 17.8.3. Technology Platform
      • 17.8.4. Neoantigen Type
      • 17.8.5. Cancer Type
      • 17.8.6. Delivery Route
      • 17.8.7. Therapy Type
      • 17.8.8. Development Phase
      • 17.8.9. End User
    • 17.9. Indonesia Neoantigen Cancer Vaccines Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Vaccine Type
      • 17.9.3. Technology Platform
      • 17.9.4. Neoantigen Type
      • 17.9.5. Cancer Type
      • 17.9.6. Delivery Route
      • 17.9.7. Therapy Type
      • 17.9.8. Development Phase
      • 17.9.9. End User
    • 17.10. Malaysia Neoantigen Cancer Vaccines Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Vaccine Type
      • 17.10.3. Technology Platform
      • 17.10.4. Neoantigen Type
      • 17.10.5. Cancer Type
      • 17.10.6. Delivery Route
      • 17.10.7. Therapy Type
      • 17.10.8. Development Phase
      • 17.10.9. End User
    • 17.11. Thailand Neoantigen Cancer Vaccines Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Vaccine Type
      • 17.11.3. Technology Platform
      • 17.11.4. Neoantigen Type
      • 17.11.5. Cancer Type
      • 17.11.6. Delivery Route
      • 17.11.7. Therapy Type
      • 17.11.8. Development Phase
      • 17.11.9. End User
    • 17.12. Vietnam Neoantigen Cancer Vaccines Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Vaccine Type
      • 17.12.3. Technology Platform
      • 17.12.4. Neoantigen Type
      • 17.12.5. Cancer Type
      • 17.12.6. Delivery Route
      • 17.12.7. Therapy Type
      • 17.12.8. Development Phase
      • 17.12.9. End User
    • 17.13. Rest of Asia Pacific Neoantigen Cancer Vaccines Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Vaccine Type
      • 17.13.3. Technology Platform
      • 17.13.4. Neoantigen Type
      • 17.13.5. Cancer Type
      • 17.13.6. Delivery Route
      • 17.13.7. Therapy Type
      • 17.13.8. Development Phase
      • 17.13.9. End User
  • 18. Middle East Neoantigen Cancer Vaccines Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. Middle East Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Vaccine Type
      • 18.3.2. Technology Platform
      • 18.3.3. Neoantigen Type
      • 18.3.4. Cancer Type
      • 18.3.5. Delivery Route
      • 18.3.6. Therapy Type
      • 18.3.7. Development Phase
      • 18.3.8. End User
      • 18.3.9. Country
        • 18.3.9.1. Turkey
        • 18.3.9.2. UAE
        • 18.3.9.3. Saudi Arabia
        • 18.3.9.4. Israel
        • 18.3.9.5. Rest of Middle East
    • 18.4. Turkey Neoantigen Cancer Vaccines Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Vaccine Type
      • 18.4.3. Technology Platform
      • 18.4.4. Neoantigen Type
      • 18.4.5. Cancer Type
      • 18.4.6. Delivery Route
      • 18.4.7. Therapy Type
      • 18.4.8. Development Phase
      • 18.4.9. End User
    • 18.5. UAE Neoantigen Cancer Vaccines Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Vaccine Type
      • 18.5.3. Technology Platform
      • 18.5.4. Neoantigen Type
      • 18.5.5. Cancer Type
      • 18.5.6. Delivery Route
      • 18.5.7. Therapy Type
      • 18.5.8. Development Phase
      • 18.5.9. End User
    • 18.6. Saudi Arabia Neoantigen Cancer Vaccines Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Vaccine Type
      • 18.6.3. Technology Platform
      • 18.6.4. Neoantigen Type
      • 18.6.5. Cancer Type
      • 18.6.6. Delivery Route
      • 18.6.7. Therapy Type
      • 18.6.8. Development Phase
      • 18.6.9. End User
    • 18.7. Israel Neoantigen Cancer Vaccines Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Vaccine Type
      • 18.7.3. Technology Platform
      • 18.7.4. Neoantigen Type
      • 18.7.5. Cancer Type
      • 18.7.6. Delivery Route
      • 18.7.7. Therapy Type
      • 18.7.8. Development Phase
      • 18.7.9. End User
    • 18.8. Rest of Middle East Neoantigen Cancer Vaccines Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Vaccine Type
      • 18.8.3. Technology Platform
      • 18.8.4. Neoantigen Type
      • 18.8.5. Cancer Type
      • 18.8.6. Delivery Route
      • 18.8.7. Therapy Type
      • 18.8.8. Development Phase
      • 18.8.9. End User
  • 19. Africa Neoantigen Cancer Vaccines Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Africa Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Vaccine Type
      • 19.3.2. Technology Platform
      • 19.3.3. Neoantigen Type
      • 19.3.4. Cancer Type
      • 19.3.5. Delivery Route
      • 19.3.6. Therapy Type
      • 19.3.7. Development Phase
      • 19.3.8. End User
      • 19.3.9. Country
        • 19.3.9.1. South Africa
        • 19.3.9.2. Egypt
        • 19.3.9.3. Nigeria
        • 19.3.9.4. Algeria
        • 19.3.9.5. Rest of Africa
    • 19.4. South Africa Neoantigen Cancer Vaccines Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Vaccine Type
      • 19.4.3. Technology Platform
      • 19.4.4. Neoantigen Type
      • 19.4.5. Cancer Type
      • 19.4.6. Delivery Route
      • 19.4.7. Therapy Type
      • 19.4.8. Development Phase
      • 19.4.9. End User
    • 19.5. Egypt Neoantigen Cancer Vaccines Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Vaccine Type
      • 19.5.3. Technology Platform
      • 19.5.4. Neoantigen Type
      • 19.5.5. Cancer Type
      • 19.5.6. Delivery Route
      • 19.5.7. Therapy Type
      • 19.5.8. Development Phase
      • 19.5.9. End User
    • 19.6. Nigeria Neoantigen Cancer Vaccines Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Vaccine Type
      • 19.6.3. Technology Platform
      • 19.6.4. Neoantigen Type
      • 19.6.5. Cancer Type
      • 19.6.6. Delivery Route
      • 19.6.7. Therapy Type
      • 19.6.8. Development Phase
      • 19.6.9. End User
    • 19.7. Algeria Neoantigen Cancer Vaccines Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Vaccine Type
      • 19.7.3. Technology Platform
      • 19.7.4. Neoantigen Type
      • 19.7.5. Cancer Type
      • 19.7.6. Delivery Route
      • 19.7.7. Therapy Type
      • 19.7.8. Development Phase
      • 19.7.9. End User
    • 19.8. Rest of Africa Neoantigen Cancer Vaccines Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Vaccine Type
      • 19.8.3. Technology Platform
      • 19.8.4. Neoantigen Type
      • 19.8.5. Cancer Type
      • 19.8.6. Delivery Route
      • 19.8.7. Therapy Type
      • 19.8.8. Development Phase
      • 19.8.9. End User
  • 20. South America Neoantigen Cancer Vaccines Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. South America Neoantigen Cancer Vaccines Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Vaccine Type
      • 20.3.2. Technology Platform
      • 20.3.3. Neoantigen Type
      • 20.3.4. Cancer Type
      • 20.3.5. Delivery Route
      • 20.3.6. Therapy Type
      • 20.3.7. Development Phase
      • 20.3.8. End User
      • 20.3.9. Country
        • 20.3.9.1. Brazil
        • 20.3.9.2. Argentina
        • 20.3.9.3. Rest of South America
    • 20.4. Brazil Neoantigen Cancer Vaccines Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Component Vaccine Type
      • 20.4.3. Technology Platform
      • 20.4.4. Neoantigen Type
      • 20.4.5. Cancer Type
      • 20.4.6. Delivery Route
      • 20.4.7. Therapy Type
      • 20.4.8. Development Phase
      • 20.4.9. End User
    • 20.5. Argentina Neoantigen Cancer Vaccines Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Vaccine Type
      • 20.5.3. Technology Platform
      • 20.5.4. Neoantigen Type
      • 20.5.5. Cancer Type
      • 20.5.6. Delivery Route
      • 20.5.7. Therapy Type
      • 20.5.8. Development Phase
      • 20.5.9. End User
    • 20.6. Rest of South America Neoantigen Cancer Vaccines Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Vaccine Type
      • 20.6.3. Technology Platform
      • 20.6.4. Neoantigen Type
      • 20.6.5. Cancer Type
      • 20.6.6. Delivery Route
      • 20.6.7. Therapy Type
      • 20.6.8. Development Phase
      • 20.6.9. End User
  • 21. Key Players/ Company Profile
    • 21.1. Agenus Inc.
      • 21.1.1. Company Details/ Overview
      • 21.1.2. Company Financials
      • 21.1.3. Key Customers and Competitors
      • 21.1.4. Business/ Industry Portfolio
      • 21.1.5. Product Portfolio/ Specification Details
      • 21.1.6. Pricing Data
      • 21.1.7. Strategic Overview
      • 21.1.8. Recent Developments
    • 21.2. BioNTech SE
    • 21.3. Creative Biolabs
    • 21.4. Geneos Therapeutics, Inc.
    • 21.5. Intavis Peptide Services GmbH
    • 21.6. ISA Pharmaceuticals B.V.
    • 21.7. Moderna, Inc.
    • 21.8. NEC Bio B.V.
    • 21.9. Neogene Therapeutics (AstraZeneca plc)
    • 21.10. Nouscom AG
    • 21.11. Nykode Therapeutics AS
    • 21.12. The Merck Group
    • 21.13. Others

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation